Ian Nicholson (F2G)
August 12, 2020 06:57 AM EDTUpdated 07:36 AM
Financing

No­vo backs 'break­through' an­ti­fun­gal play­er's $60M round — with a fo­cus on rare mold in­fec­tions

Amber Tong

The plight of an­tibi­otics de­vel­op­ers has been well doc­u­ment­ed: chron­i­cal­ly un­der­fund­ed re­search, daunt­ing sci­en­tif­ic chal­lenges, and lit­tle com­mer­cial up­side even for the ones that make …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times